

UNITED STATES
PATENT AND TRADEMARK OFFICE



A faint, light gray technical drawing of a mechanical assembly, possibly a piston or engine component, serves as the background for the upper half of the slide. It features various parts labeled with numbers such as 80, 84, 86, 82, 34, 32, 52, and 50.

Patent Trial and Appeal Board Parallel Litigation Study

June 2022

(Data from Jan. 1, 2019 through Dec. 31, 2021)




Parallel litigation: overview

- **Parallel litigation:** a scenario in which petitioner, patent owner, and the patent at issue are simultaneously engaged in a PTAB proceeding and litigation in another venue.
- The vast majority of petitioners (about 80% or higher) have been sued by patent owners in another venue prior to filing their petitions.



Parallel litigation: key cases



Parallel litigation: key cases

NHK Spring Co., Ltd. v. Intri-Plex Techs., Inc., Case IPR2018-00752, Paper 8 (Sept. 12, 2018) (designated precedential May 7, 2019)

- Denying institution because (1) the prior art was previously considered and (2) co-pending district court proceeding was nearing completion
- First decision on institution to explicitly cite a parallel litigation's advanced state as a reason for denying the petition
- Same invalidity challenges were involved in the PTAB and district court proceedings



Parallel litigation: key cases

Apple Inc. v. Fintiv, Inc., Case IPR2020-00019, Paper 11 (March 20, 2020) (designated precedential May 5, 2020)

- Provided a non-exclusive list of factors that the PTAB considers in exercising discretion on instituting *inter partes* review because of parallel district court litigation

Note: Because of the prominence of *NHK* and *Fintiv* within the topic of discretionary denials based on parallel litigation, the topic is often synonymously referred to as "*NHK/Fintiv*" or "*Fintiv*," even regarding cases decided in FY19 and the beginning of FY20, before the *Fintiv* decision issued.



Parallel litigation: key cases

Denial of institution based on *NHK/Fintiv* often can be avoided by stipulating that the petitioner will not pursue similar arguments in the parallel litigation.

- *Sand Revolution II, LLC v. Continental Intermodal Group – Trucking LLC*, Case IPR2019-01393, Paper 24 (June 16, 2020) (designated informative July 13, 2020) (decision on rehearing of denial, instituting review when the *Fintiv* factors weighed against exercising discretion to deny institution because petitioner filed a stipulation to not assert the “same grounds” in district court).
- *Sotera Wireless, Inc. v. Masimo Corporation* (§ II.A), IPR2020-01019, Paper 12 (Dec. 1, 2020) (designated precedential Dec. 17, 2020) (instituting review when petitioner filed a broad stipulation to not assert in district court grounds “raised or that could have been reasonably raised in an IPR”).



Parallel litigation: summary

- After *Fintiv* was designated precedential, discretionary denial based on parallel litigation has been raised in about half of all cases in which petitioner was sued by patent owners in another venue
- The number of cases denying institution dropped significantly after peaking during the first half of fiscal year 2021
- Stipulation filings increased after *Sotera* was designated precedential, and Decisions on Institution (DIs) noting stipulations frequently avoid denials based on *NHK/Fintiv*
- The majority of cases involving an *NHK/Fintiv* issue involved co-pending litigation in one of the Western District of Texas, the Eastern District of Texas, and the District of Delaware
 - The Western District of Texas was the venue most frequently discussed in DIs analyzing *NHK/Fintiv*, and, during the study period, no corresponding petitions were denied based on *NHK/Fintiv* since August 2021



Parallel litigation: methodology

- All DIs and patent owner preliminary responses (POPRs) in each *inter partes* review (IPR), covered business method review (CBM), and post grant review (PGR) in the indicated time periods during Fiscal Years 2019 through 2022 (FY19–22) were reviewed to capture information regarding the *NHK/Fintiv* issue.
- The appendix (a separate document posted with this presentation) includes definitions and further methodology details.



***NHK/Fintiv* issue frequency**


***NHK/Fintiv* issue frequency: definitions**

- a. the DI analyzed *NHK/Fintiv*; or
- b. patent owner argued for denying institution based on *NHK/Fintiv* in its POPR and *NHK/Fintiv* was not addressed in the corresponding DI because, for example, the DI denied institution on the merits or the case terminated prior to PTAB issuing a DI.
 - *NHK/Fintiv* was not considered raised if the Petition raised *NHK/Fintiv* preemptively, but the POPR did not raise *NHK/Fintiv* and the DI did not analyze *NHK/Fintiv*.



NHK/*Fintiv* issue frequency

(FY19 Q2 to FY22 Q1: Jan. 1, 2019 to Dec. 31, 2021)



After *Fintiv* was designated precedential, parallel litigation was raised in about 40% of all cases, regardless of whether ultimately there was an institution.

uspto

***NHK/Fintiv* issue frequency: summary**

- After *NHK* was designated precedential (FY19 Q2):
 - *NHK* was raised in about 10-15% of cases.
- After *Fintiv* was designated precedential (FY20 Q3):
 - *NHK/Fintiv* was raised in about 40% of cases.



***NHK/Fintiv* outcomes**

***NHK/Fintiv* outcomes: definitions**


(1) The next graphic (slide 16) depicts the number of DIs analyzing *NHK/Fintiv* and (2) the following graphic (slide 17) depicts DIs that analyzed *NHK/Fintiv* as a percentage of all cases.

- **The orange bars** represent DIs denying institution in which *NHK/Fintiv* was at least one reason for denial.
- **The light blue bars** represent DIs instituting trial that analyzed *NHK/Fintiv*.
- **The gray bars** (slide 16 graphic only) represent all other cases through institution (i.e., cases in which DIs did not analyze *NHK/Fintiv* and POPR did not raise *NHK/Fintiv* plus cases resulting in pre-DI terminations).
 - If the DI noted, but did not substantively address, an *NHK/Fintiv* issue (e.g., in a denial on the merits), the DI did not analyze *NHK/Fintiv*.



NHK/Fintiv outcomes

(FY19 Q2 to FY22 Q1: Jan. 1, 2019 to Dec. 31, 2021)




NHK/Fintiv
denials
peaked in
FY21 Q2
and
dropped
significantly
afterwards.

uspto

NHK/Fintiv outcomes

(FY19 Q2 to FY22 Q1: Jan. 1, 2019 to Dec. 31, 2021)



Most cases
do not
address
NHK/Fintiv.

uspto


NHK/Fintiv outcomes: definitions

- If the DI noted, but did not substantively address, an *NHK/Fintiv* issue (e.g., in a denial on the merits), the DI did not analyze *NHK/Fintiv*.
- The light gray bar (when present) represents cases in which the POPR argued *NHK/Fintiv* but the case terminated prior to PTAB issuing a DI.
- The purple bar represents cases in which *NHK/Fintiv* was raised but PTAB did not address *NHK/Fintiv* in the DI because institution was denied for other reasons (e.g., a denial on the merits).
- The orange bar represents DIs denying institution that identify *NHK/Fintiv* as at least one reason for denial.
- The light blue bar represents DIs instituting trial that analyzed *NHK/Fintiv*.



NHK/Fintiv outcomes for FY19


(FY19 Q2 to Q4: Jan. 1, 2019 to Sept. 30, 2019)



uspto


NHK/Fintiv outcomes for FY20

(FY20: Oct. 1, 2019 to Sept. 30, 2020)



NHK/Fintiv outcomes for FY21

(FY21: Oct. 1, 2020 to Sept. 30, 2021)




DIs **denying institution** (at least in part) because of *NHK/Fintiv*. Peaked at about **11%** of all outcomes in FY21 Q1 and Q2 and fell to about **5%** of all outcomes in FY21 Q4 for an FY21 average of about **8%**.

uspto

NHK/Fintiv outcomes for FY22 Q1

(FY22 Q1: Oct. 1, 2021 to Dec. 31, 2021)



uspto

***NHK/Fintiv* outcomes: summary**


DIs denying institution (at least in part) because of *NHK/Fintiv*:

- Were about **1%** of all outcomes in FY19 Q2 to Q4.
- Were about **4%** of all outcomes in FY20.
- Peaked at about **11%** of all outcomes in a quarter in FY21 Q1 and Q2.
- Fell to about **2%** of all outcomes in a quarter by FY22 Q1.



***Fintiv* outcomes in Orange Book-listed and biologic drug patent challenges**

*Decisions on Institution for petitions challenging drug patents
(May 5, 2020 - March 31, 2022)*



PTAB has denied only **three total** AIA petitions, challenging **two drug patents** under *Fintiv*.




Stipulations in an *NHK/Fintiv* analysis

***NHK/Fintiv* stipulations**

NHK/Fintiv stipulations

Outcomes for DIs in which stipulations are noted
(FY20 Q3 to FY22 Q1: Apr. 1, 2020 to Dec. 31, 2021)




Most DIs noting a stipulation **do not deny** based on *NHK/Fintiv*.

uspto

NHK/Fintiv stipulations:

Outcomes for DIs in which stipulations are noted
(FY20 Q3 to FY22 Q1: Apr. 1, 2020 to Dec. 31, 2021)



After *Sotera*,
stipulation filings
increased;
by Q3 of FY21,
DIs noting a
stipulation did
not frequently
deny institution
based on
NHK/Fintiv.

uspto

***NHK/Fintiv* stipulations: summary**

- After *Sand* was designated informative in FY20 Q4:
 - The number of stipulations filed increased.
- After *Sotera* was designated precedential in FY21 Q1:
 - The number of stipulations filed increased further.
 - DIs analyzing *NHK/Fintiv* and noting a stipulation frequently resulted in avoiding an *NHK/Fintiv* denial.




***NHK/Fintiv* parallel litigation venues**

***NHK/Fintiv* parallel litigation venues**

***NHK/Fintiv* parallel litigation venues**


(FY19 Q2 to FY22 Q1: Jan. 1, 2019 to Dec. 31, 2021)



uspto

***NHK/Fintiv* parallel litigation venues**

(FY19 Q2 to FY22 Q1: Jan. 1, 2019 to Dec. 31, 2021)



***NHK/Fintiv* parallel litigation venues: summary**

- In about 60% of *NHK/Fintiv* analyses in the studied quarters for FY19 to FY22, in which a parallel litigation venue was identified, the identified district court was one of the Western District of Texas, the Eastern District of Texas, and the District of Delaware.
- In FY21, the Western District of Texas was the venue identified as the most frequently discussed in DIs analyzing *NHK/Fintiv*.
- The Eastern District of Texas is the venue with the most *NHK/Fintiv* denials.



Questions / comments?

PTABStatisticsQuestions@uspto.gov

www.uspto.gov/patents/ptab/statistics



